tweetindex
EN

Daphne Zohar ✓

@daphnezohar · Seaport, Boston MA · joined 25 Jun 2009

Founder, Board & CEO of @SeaportTX. Co-founder Karuna Tx (now at BMS). previously Founder, Board & CEO PureTech. Cofounder/Executive Producer @BiotechCH.

26 924Followers
795Following
9 368Posts total
89.2KViews on collected posts

Latest posts

This account is NOT me in case it engages w you. I’ve reported but doesn’t seem to help. Its Daphnezoharn beware as they may try to hack your account by sending you DMs https://t.co/Tlp51kFo62
3.1K views · 29 likes · 0 reposts · 4 replies Open on X →
Mike Rea takes 44 of the largest-selling branded drugs since 1996 & maps “effective duration” in peak years: how many years at peak to earn what the drug actually earned across its ramp, plateau, and decline. 12 peak-years for a chronic disease blockbuster give or take 2. Acute
https://asymmetriclearning.substack.com/p/high-long-both
9.9K views · 88 likes · 13 reposts · 8 replies Open on X →
Discussion w the senior BD leaders at big pharma and one surprising point made is that more than one said that they are focused on earlier stage and are comfortable with clinical risk. They don’t seem to be shaken up by avidity/$NVS recent post deal setback. “In BD, risk is your 25.1K views · 144 likes · 15 reposts · 11 replies Open on X →
@daphnezohar @monaco_biotech Let’s hope this comes from the same people who think we’re going to cure all disease by 2030 210 views · 2 likes · 0 reposts · 0 replies Open on X →
@daphnezohar No good deed goes unpunished 527 views · 4 likes · 0 reposts · 0 replies Open on X →
@daphnezohar SV Investors: That's amazing. Here's a Billion dollars, although we only want a little bit of your company because it's obviously worth a trillion dollars because billions aren't cool anymore. Also sauna and cold plunge. 298 views · 4 likes · 0 reposts · 0 replies Open on X →
Developing medicines that could help save people’s lives is highly regulated & takes over a decade. Biopharma is cast as a villain despite painstakingly process w patients at the forefront. AI companies: “We believe our technology could end civilization in the next decade” 41.7K views · 157 likes · 23 reposts · 13 replies Open on X →
Useful free tool tracks a number of key parameters in one place based on regulatory filings rather than press releases (changes to endpoints/timelines, funding runway and catalyst timing discrepancies, ownership etc). https://t.co/IPQJznahPD by @insidepharma $XBI $IBB $BBC https:
8.4K views · 58 likes · 7 reposts · 3 replies Open on X →

Against accounts of the same size

8 posts from the last 90 days, next to the 10K–100K follower range. shown widely, but few of those viewers react.

Median views5 724this account924median for 10K–100K
Reach, %21.26%this account3.62%median for 10K–100K
Engagement, %0.88%this account1.52%median for 10K–100K
MetricThis accountMedian for 10K–100KRatio
Median views per post5 7249246.20×
Reach (views ÷ followers)21.26%3.62%5.87×
Engagement rate0.88%1.52%0.58×

Others in this range →   Compare with another account →   How these benchmarks are built →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

8.4K25 Aug
41.7K9 Sep
298
527
210
25.1K15 Sep
9.9K19 Sep
3.1K21 Sep

Last 8 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.81%25 Aug
0.47%9 Sep
1.34%
0.76%
0.95%
0.69%15 Sep
1.10%19 Sep
1.07%21 Sep

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.52%.

What the audience does

Likes61.9%486 in total
Reposts7.4%58 in total
Replies5.0%39 in total
Quotes0.8%6 in total
Bookmarks25.0%196 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

Similar accounts